Bli medlem
Bli medlem

Du är här

2016-11-23

Bavarian Nordic A/S: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine

* Second and final Phase 3 study to support a U.S. registration of
liquid-frozen IMVAMUNE

COPENHAGEN, Denmark, November 23, 2016
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the completion
of enrollment of a Phase 3 clinical study designed to demonstrate
non-inferiority between its investigational, non-replicating smallpox
vaccine, IMVAMUNE and ACAM2000, the current U.S. licensed, and replicating
smallpox vaccine. This is the second and final study agreed with the U.S.
Food and Drug Administration (FDA) to support the registration of
liquid-frozen IMVAMUNE. The first study, a lot consistency study in 4,000
healthy individuals, was successfully completed in 2015.

The Phase 3 non-inferiority study enrolled 440 subjects at a U.S. military
garrison in South Korea led by the United States Army Medical Research
Institute of Infectious Diseases (USAMRIID) in collaboration with the U.S.
Defense Health Agency. All subjects will have completed the study within
second quarter of 2017, and top line data is anticipated in the second half
of 2017.

Paul Chaplin, President&Chief Executive Officer of Bavarian Nordic, said:
"Completion of enrolment of this study represents a significant milestone in
the collaboration between Bavarian Nordic, and multiple federal agencies.
IMVAMUNE has served as the cornerstone for our Company over the past decade
and we will continue to work with the U.S. Government to meet their stated
goal of protecting 66 million Americans who are in need of a safer smallpox
vaccine. We look forward reporting these data and working with the
authorities in the process towards U.S. licensure."

Bavarian Nordic has to-date delivered 28 million doses of liquid-frozen
IMVAMUNE to the U.S. Strategic National Stockpile.

Federal funding acknowledgments
The Phase 3 study comparing the safety and immunogenicity of IMVAMUNE to
ACAM2000 has been funded in whole or in part with Federal funds from the
Office of the Assistant Secretary for Preparedness and Response, Biomedical
Advanced Research and Development Authority, under Contract No.
HHSO100200700034C

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies
and vaccines for infectious diseases, based on the Company's live virus
vaccine platform. Through long-standing collaborations, including a
collaboration with the U.S. government, Bavarian Nordic has developed a
portfolio of vaccines for infectious diseases, including the non-replicating
smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the
United States and other governments. The vaccine is approved in the European
Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are developing an Ebola vaccine regimen, which has been
fast-tracked, with the backing of worldwide health authorities, and a vaccine
for the prevention and treatment of HPV. Additionally, in collaboration with
the National Cancer Institute, Bavarian Nordic has developed a portfolio of
active cancer immunotherapies, including PROSTVAC®, which is currently in
Phase 3 clinical development for the treatment of advanced prostate cancer.
The company has partnered with Bristol-Myers Squibb for the potential
commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control,
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. We undertake no obligation to publicly update or
revise forward-looking statements to reflect subsequent events or
circumstances after the date made, except as required by law.

Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

Company Announcement no. 30 / 2016

2016-30-en
http://hugin.info/100065/R/2058914/771658.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.